Symbols / MIRA $1.08 -2.70% MIRA Pharmaceuticals, Inc.
MIRA Chart
About
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Gen | Market Cap | 45.38M |
| Enterprise Value | 36.19M | Income | -32.00M | Sales | — |
| Book/sh | 0.19 | Cash/sh | 0.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -2.63 | PEG | — |
| P/S | — | P/B | 5.65 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 15.71 |
| Current Ratio | 15.75 | Debt/Eq | 5.51 | LT Debt/Eq | — |
| EPS (ttm) | -1.35 | EPS next Y | -0.41 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 07:00 | ROA | -93.58% |
| ROE | -165.87% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 42.02M |
| Shs Float | 35.00M | Short Float | 0.90% | Short Ratio | 2.46 |
| Short Interest | — | 52W High | 2.45 | 52W Low | 0.78 |
| Beta | — | Avg Volume | 163.78K | Volume | 81.33K |
| Target Price | — | Recom | None | Prev Close | $1.11 |
| Price | $1.08 | Change | -2.70% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.08
Latest analyst target
3. DCF / Fair value
$-3.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.08
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-09-30 | init | Rodman & Renshaw | — → Buy | $17 |
| 2024-08-05 | init | Ascendiant Capital | — → Buy | $11 |
- Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making - MSN Mon, 06 Apr 2026 06
- MIRA Stock Price, Quote & Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill Wed, 01 Apr 2026 07
- MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 03 Apr 2026 00
- MIRA Pharmaceuticals (MIRA) CEO granted 83,500 RSUs - Stock Titan Wed, 01 Apr 2026 21
- MIRA Pharmaceuticals : Investor Presentation - marketscreener.com Mon, 06 Apr 2026 23
- What's Going On With MIRA Pharma Stock Tuesday? - Benzinga ue, 24 Mar 2026 13
- Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Drops By 13.9% - MarketBeat ue, 17 Mar 2026 07
- MIRA Explodes 23% on Groundbreaking Pain Research; Can This Surge Sustain? - Bitget Mon, 23 Mar 2026 07
- MIRA pain drug showed morphine-like relief without THC-like effects - Stock Titan Mon, 23 Mar 2026 07
- Nvidia Stock (NVDA) Climbs on Multi-Year AI Deal with Mira Murati’s Thinking Machines Lab - tipranks.com ue, 10 Mar 2026 07
- Mira Pharmaceuticals increases at-the-market offering by $15.2 million - Investing.com Fri, 05 Dec 2025 08
- MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com ue, 31 Mar 2026 18
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 24 Mar 2026 07
- Hospitals, airports adopt MIRA as Visionstate's compliance subscriptions climb - Stock Titan Wed, 18 Mar 2026 07
- MIRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Sat, 14 Feb 2026 05
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
10.49
+30.86%
|
8.02
-5.95%
|
8.53
+20.97%
|
7.05
|
| Research And Development |
|
1.72
-47.97%
|
3.31
+110.15%
|
1.57
-33.11%
|
2.35
|
| Selling General And Administration |
|
8.77
+86.16%
|
4.71
-27.49%
|
6.50
+117.22%
|
2.99
|
| General And Administrative Expense |
|
8.77
+86.16%
|
4.71
-27.49%
|
6.50
+117.22%
|
2.99
|
| Other Gand A |
|
8.77
+86.16%
|
4.71
-27.49%
|
6.50
+117.22%
|
2.99
|
| Other Operating Expenses |
|
—
|
—
|
0.45
-73.39%
|
1.70
|
| Total Expenses |
|
10.49
+30.86%
|
8.02
-5.95%
|
8.53
+20.97%
|
7.05
|
| Operating Income |
|
-10.49
-30.86%
|
-8.02
+5.95%
|
-8.53
-20.97%
|
-7.05
|
| EBITDA |
|
-10.49
-30.86%
|
-8.02
+5.95%
|
-8.53
-20.97%
|
-7.05
|
| Normalized EBITDA |
|
-10.46
-30.42%
|
-8.02
+5.95%
|
-8.53
-20.97%
|
-7.05
|
| EBIT |
|
-10.49
-30.86%
|
-8.02
+5.95%
|
-8.53
-20.97%
|
-7.05
|
| Total Unusual Items |
|
-0.04
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-0.04
|
—
|
—
|
—
|
| Net Income |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Pretax Income |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Non Operating Interest Income Expense |
|
0.10
-40.30%
|
0.17
+104.79%
|
-3.46
-33619.94%
|
-0.01
|
| Interest Expense Non Operating |
|
—
|
—
|
3.46
+33619.94%
|
0.01
|
| Net Interest Income |
|
0.10
-40.30%
|
0.17
+104.79%
|
-3.46
-33619.94%
|
-0.01
|
| Interest Expense |
|
—
|
—
|
3.46
+33619.94%
|
0.01
|
| Interest Income Non Operating |
|
0.10
-40.30%
|
0.17
|
—
|
—
|
| Interest Income |
|
0.10
-40.30%
|
0.17
|
—
|
—
|
| Other Income Expense |
|
-0.05
|
—
|
—
|
—
|
| Other Non Operating Income Expenses |
|
-0.01
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
-0.04
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Income From Continuing And Discontinued Operation |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Income Continuous Operations |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Normalized Income |
|
-10.41
-32.53%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Net Income Common Stockholders |
|
-32.00
-307.50%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Otherunder Preferred Stock Dividend |
|
21.56
|
0.00
|
—
|
—
|
| Diluted EPS |
|
-1.35
-164.71%
|
-0.51
+40.00%
|
-0.85
-113.77%
|
-0.40
|
| Basic EPS |
|
-1.35
-164.71%
|
-0.51
+40.00%
|
-0.85
-113.77%
|
-0.40
|
| Basic Average Shares |
|
23.69
+53.42%
|
15.44
+10.91%
|
13.92
-21.55%
|
17.75
|
| Diluted Average Shares |
|
23.69
+53.42%
|
15.44
+10.91%
|
13.92
-21.55%
|
17.75
|
| Diluted NI Availto Com Stockholders |
|
-32.00
-307.50%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Total Other Finance Cost |
|
—
|
-0.17
-104.79%
|
3.46
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
11.09
+279.52%
|
2.92
-40.74%
|
4.93
+474.83%
|
0.86
|
| Current Assets |
|
11.06
+282.95%
|
2.89
-40.56%
|
4.86
+882.64%
|
0.49
|
| Cash Cash Equivalents And Short Term Investments |
|
11.03
+289.35%
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
|
| Cash And Cash Equivalents |
|
6.35
+124.04%
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
|
| Cash Financial |
|
6.35
+124.04%
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
|
| Other Short Term Investments |
|
4.68
|
0.00
|
—
|
—
|
| Receivables |
|
—
|
0.00
-100.00%
|
0.01
|
0.00
|
| Other Receivables |
|
—
|
—
|
0.01
|
—
|
| Prepaid Assets |
|
0.03
-48.57%
|
0.05
-77.55%
|
0.24
|
0.00
|
| Current Deferred Assets |
|
—
|
—
|
0.00
-100.00%
|
0.14
|
| Total Non Current Assets |
|
0.04
+0.00%
|
0.04
-52.25%
|
0.07
-79.59%
|
0.36
|
| Net PPE |
|
—
|
0.00
-100.00%
|
0.01
-98.61%
|
0.36
|
| Gross PPE |
|
—
|
0.00
-100.00%
|
0.01
-98.61%
|
0.36
|
| Other Properties |
|
—
|
—
|
0.01
-98.61%
|
0.36
|
| Non Current Accounts Receivable |
|
0.04
+0.00%
|
0.04
-48.75%
|
0.07
|
—
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
0.70
-2.94%
|
0.72
+29.61%
|
0.56
-61.62%
|
1.45
|
| Current Liabilities |
|
0.70
-2.94%
|
0.72
+29.61%
|
0.56
-59.26%
|
1.37
|
| Payables And Accrued Expenses |
|
0.70
-2.94%
|
0.72
+30.80%
|
0.55
-42.58%
|
0.96
|
| Payables |
|
0.70
-2.94%
|
0.72
+34.31%
|
0.54
-40.53%
|
0.91
|
| Accounts Payable |
|
0.13
-82.14%
|
0.72
+34.31%
|
0.54
-31.76%
|
0.79
|
| Current Accrued Expenses |
|
—
|
0.00
-100.00%
|
0.01
-74.84%
|
0.06
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.01
-98.76%
|
0.41
|
| Current Debt |
|
—
|
—
|
—
|
0.13
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.01
-98.15%
|
0.27
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.08
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.08
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.08
|
| Stockholders Equity |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Common Stock Equity |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Capital Stock |
|
0.00
+153.26%
|
0.00
+12.04%
|
0.00
-77.80%
|
0.01
|
| Common Stock |
|
0.00
+153.26%
|
0.00
+12.04%
|
0.00
-77.80%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
41.94
+153.24%
|
16.56
+12.04%
|
14.78
+0.24%
|
14.75
|
| Ordinary Shares Number |
|
41.94
+153.24%
|
16.56
+12.04%
|
14.78
+0.24%
|
14.75
|
| Additional Paid In Capital |
|
49.97
+59.46%
|
31.34
+22.13%
|
25.66
+194.92%
|
8.70
|
| Retained Earnings |
|
-39.58
-35.84%
|
-29.14
-36.89%
|
-21.29
-128.80%
|
-9.30
|
| Total Equity Gross Minority Interest |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Total Capitalization |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Working Capital |
|
10.36
+378.49%
|
2.16
-49.67%
|
4.30
+591.09%
|
-0.88
|
| Invested Capital |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+1044.44%
|
-0.46
|
| Total Debt |
|
—
|
0.00
-100.00%
|
0.01
-98.97%
|
0.49
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
0.01
-98.59%
|
0.36
|
| Net Tangible Assets |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Tangible Book Value |
|
10.39
+372.40%
|
2.20
-49.71%
|
4.37
+833.67%
|
-0.60
|
| Duefrom Related Parties Non Current |
|
0.04
+0.00%
|
0.04
-48.75%
|
0.07
|
0.00
|
| Dueto Related Parties Current |
|
0.57
|
0.00
|
0.00
-100.00%
|
0.12
|
| Interest Payable |
|
—
|
0.00
-100.00%
|
0.01
-58.64%
|
0.03
|
| Line Of Credit |
|
—
|
—
|
0.00
-100.00%
|
0.13
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.66
+16.17%
|
-5.56
-22.69%
|
-4.53
+19.13%
|
-5.60
|
| Cash Flow From Continuing Operating Activities |
|
-4.66
+16.17%
|
-5.56
-22.69%
|
-4.53
+19.13%
|
-5.60
|
| Net Income From Continuing Operations |
|
-10.44
-32.98%
|
-7.85
+34.46%
|
-11.98
-69.77%
|
-7.06
|
| Other Non Cash Items |
|
—
|
—
|
5.54
+53935.92%
|
0.01
|
| Stock Based Compensation |
|
6.31
+228.67%
|
1.92
-24.70%
|
2.55
+96.74%
|
1.30
|
| Unrealized Gain Loss On Investment Securities |
|
0.04
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-0.57
-252.88%
|
0.37
+158.04%
|
-0.64
-536.41%
|
0.15
|
| Change In Receivables |
|
0.00
-100.00%
|
0.01
+200.00%
|
-0.01
|
0.00
|
| Changes In Account Receivables |
|
—
|
0.01
+200.00%
|
-0.01
|
0.00
|
| Change In Prepaid Assets |
|
0.03
-85.94%
|
0.19
+177.55%
|
-0.24
|
0.00
|
| Change In Payables And Accrued Expense |
|
-0.59
-448.86%
|
0.17
+143.72%
|
-0.39
-356.13%
|
0.15
|
| Change In Accrued Expense |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Change In Payable |
|
-0.59
-421.53%
|
0.18
+147.44%
|
-0.39
|
—
|
| Change In Account Payable |
|
-0.59
-421.53%
|
0.18
+147.44%
|
-0.39
|
—
|
| Change In Other Current Assets |
|
—
|
0.00
-100.00%
|
0.01
+200.00%
|
-0.01
|
| Change In Other Current Liabilities |
|
—
|
—
|
1.10
|
0.00
|
| Financing Cash Flow |
|
8.18
+115.66%
|
3.79
-56.84%
|
8.78
+179.19%
|
3.15
|
| Cash Flow From Continuing Financing Activities |
|
8.18
+115.66%
|
3.79
-56.84%
|
8.78
+179.19%
|
3.15
|
| Net Issuance Payments Of Debt |
|
0.57
|
0.00
-100.00%
|
1.01
+728.40%
|
-0.16
|
| Issuance Of Debt |
|
0.57
|
0.00
-100.00%
|
2.15
|
0.00
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-1.14
-614.05%
|
-0.16
|
| Long Term Debt Issuance |
|
0.57
|
0.00
|
—
|
—
|
| Net Long Term Debt Issuance |
|
0.57
|
0.00
|
—
|
—
|
| Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
2.15
|
0.00
|
| Short Term Debt Payments |
|
—
|
0.00
+100.00%
|
-1.14
-614.05%
|
-0.16
|
| Net Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
1.01
+728.40%
|
-0.16
|
| Net Common Stock Issuance |
|
7.01
+94.18%
|
3.61
-53.16%
|
7.70
+165.30%
|
2.90
|
| Proceeds From Stock Option Exercised |
|
0.89
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
-0.29
-260.33%
|
0.18
+145.60%
|
0.07
-81.53%
|
0.40
|
| Changes In Cash |
|
3.51
+298.57%
|
-1.77
-141.62%
|
4.25
+272.93%
|
-2.46
|
| Beginning Cash Position |
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
-87.51%
|
2.81
|
| End Cash Position |
|
6.35
+124.04%
|
2.83
-38.45%
|
4.60
+1211.35%
|
0.35
|
| Free Cash Flow |
|
-4.66
+16.17%
|
-5.56
-22.69%
|
-4.53
+19.13%
|
-5.60
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
—
|
| Change In Interest Payable |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Common Stock Issuance |
|
7.01
+94.18%
|
3.61
-53.16%
|
7.70
+165.30%
|
2.90
|
| Issuance Of Capital Stock |
|
7.01
+94.18%
|
3.61
-53.16%
|
7.70
+165.30%
|
2.90
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-01 View
- 10-K2026-03-31 View
- 8-K2026-03-23 View
- 8-K2026-03-03 View
- 8-K2026-02-02 View
- 8-K2025-12-22 View
- 8-K2025-12-05 View
- 10-Q2025-11-13 View
- 8-K2025-10-23 View
- 8-K2025-10-16 View
- 8-K2025-10-15 View
- 42025-10-03 View
- 42025-10-03 View
- 8-K2025-09-30 View
- 8-K2025-09-22 View
- 42025-09-18 View
- 8-K2025-09-15 View
- 8-K2025-09-11 View
- 42025-09-03 View
- 8-K2025-08-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|